International Initiative on a Refined Staging System for Medullary Thyroid Cancer: A Multinational Multicenter Study
Journal of Clinical Oncology · 04.11.2026
DOI: 10.1200/jco-26-01146 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, online erschienen am 04.11.2026. Verfasst von Xiao Shi und 50 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
PURPOSE To refine the suboptimal prognostic discrimination of the American Joint Committee on Cancer (AJCC) 8th edition TNM (TNM-8) staging system for medullary thyroid carcinoma (MTC). METHODS This retrospective study enrolled patients with MTC from 43 centers across 15 countries under the framework of the International Medullary Thyroid Cancer Staging Consortium (IMTCSC). Pooled data were analyzed with disease-specific survival as the primary end point. With M1 disease fixed in stage IVC, we redefined the schema for stages I to IVB in M0 patients. Using exhaustive enumeration, all possible TN combinations were fitted into multivariable Cox models, with the lowest Akaike information criterion (AIC) defining the proposed system. Prognostic discrimination was assessed using adjusted hazard ratios (aHRs) and the concordance index (C-index). RESULTS The IMTCSC cohort included 2,573 patients with MTC (female-to-male ratio: 1.25; median age 52 years [IQR, 41-62]; median follow-up 76.3 months [IQR, 37.3-121.0]). Level VII metastasis correlated with poorer survival, supporting its upgrade to N1c. Exhaustive search of 116,284 admissible stage-grouping schemas identified the optimal model (lowest AIC) defining stages I to IVB: I (T1N0-N1a/T2N0), II (T1N1b/T2N1a/T3N0), III (T1N1c/T2N1b/T3N1a/T4aN0-N1a), IVA (T2N1c/T3N1b-N1c/T4aN1b), and IVB (T4aN1c/T4b any N). Compared with AJCC TNM-8 (stage I as reference; stage II aHR, 0.84, P = .652; stage III aHR, 1.48, P = .172; stage IV aHR, 7.95, P < .001), the proposed system showed a clearer monotonic increase in disease-specific death risk (stage II aHR 2.22; stage III aHR, 4.81; stage IV aHR 15.75; all P ≤ .001) and a higher C-index (0.892 v 0.856, P < .001), which was also evaluated in the SEER cohort (N = 1,909). CONCLUSION The proposed MTC staging system confers an improved schema for prognostic stratification compared with AJCC TNM-8.
Autor:innen und Institutionen
- Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Departments of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
- Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research…
- Department of Clinical and Experimental Medicine, Endocrinology Unit, University of Pisa, Pisa, Italy.
- Département d'Imagerie, Gustave Roussy, Service d'Oncologie Endocrinienne, Université Paris Saclay, ENDOCAN-TUTHYREF Network, Villejuif, France.
ORCID-Profile: Xiao Shi, Qiaomu Liu, Bin Xu, Dapeng Li, Antonio Matrone, Ian Ganly, Xiangqian Zheng, Giovanni Tallini, Omar Hamdy, Mira Fink, Fabian Pitoia, João Martins Gama, Luis G Carvajal-Carmona, Quoc Dat Ngo, Domenico Salvatore, Alexander J Papachristos, Leonardo Rossi, Brian R Untch, Andreas Spörlein, Kehan Song, Kewei Jiang, Simone De Leo, Mabel E Bohórquez, Ana Patricia Estrada-Florez, Berna Evranos Ogmen, Ekin Yigit Koroglu, Dongmei Ji, Martin Schlumberger, Lori Wirth, Rossella Elisei, Ilya V Sleptsov, Young Joo Park, Mohamed-Amine Bani, Ronald A Ghossein, Anthony J Gill, Yu Wang
Zitieren
APA
Shi, X., Liu, Q., Xu, B., Li, D., Matrone, A., Hadoux, J., Ganly, I., Houot, B., Zheng, X., Wohllk, N., Cakir, B., Tallini, G., Hamdy, O., Fink, M., Pitoia, F., Gama, J. M., Carvajal-Carmona, L. G., Ngo, Q. D., Salvatore, D., …, & International Medullary Thyroid Cancer Staging Consortium (2026). International Initiative on a Refined Staging System for Medullary Thyroid Cancer: A Multinational Multicenter Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-01146
Vancouver
Shi X, Liu Q, Xu B, Li D, Matrone A, Hadoux J, et al. International Initiative on a Refined Staging System for Medullary Thyroid Cancer: A Multinational Multicenter Study. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-01146
BibTeX
@article{Shi2026,
author = {Shi, Xiao and Liu, Qiaomu and Xu, Bin and Li, Dapeng and Matrone, Antonio and Hadoux, Julien and Ganly, Ian and Houot, Benjamin and Zheng, Xiangqian and Wohllk, Nelson and Cakir, Bekir and Tallini, Giovanni and Hamdy, Omar and Fink, Mira and Pitoia, Fabian and Gama, João Martins and Carvajal-Carmona, Luis G and Ngo, Quoc Dat and Salvatore, Domenico and Papachristos, Alexander J and Sidhu, Stanley B and Rossi, Leonardo and Untch, Brian R and Spörlein, Andreas and Pham, Quoc Thang and Shen, Cenkai and Zhang, Hao and Song, Kehan and Wu, Yijun and Liu, Zhiyan and Jiang, Kewei and Wang, Chenyi and Xiao, Haipeng and De Leo, Simone and Bohórquez, Mabel E and Estrada-Florez, Ana Patricia and Ogmen, Berna Evranos and Koroglu, Ekin Yigit and Ji, Qinghai and Ji, Dongmei and Schlumberger, Martin and Wirth, Lori and Elisei, Rossella and Sleptsov, Ilya V and Park, Young Joo and Fugazzola, Laura and Bani, Mohamed-Amine and Ghossein, Ronald A and Gill, Anthony J and Wang, Yu and International Medullary Thyroid Cancer Staging Consortium, International Medullary Thyroid Cancer Staging Consortium},
title = {International Initiative on a Refined Staging System for Medullary Thyroid Cancer: A Multinational Multicenter Study},
journal = {Journal of Clinical Oncology},
year = {2026},
doi = {10.1200/jco-26-01146}
}
EUVIMED